Onkologie. 2015:9(1):10-12

Immunotherapy in treating solid tumours

Denisa Vitásková, Bohuslav Melichar

Onkologická klinika, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc

Advances, particularly in the field of molecular immunology, have opened new opportunities, allowed identification of new targets in

the immune system, and resulted in developing new anticancer agents. Some of these agents have already been approved and become

a part of standard treatment while others are in the final phases of clinical trials. These agents are of particular importance in the palliative

indication in patients with advanced disease stage who cannot be offered many treatment options. Immunotherapy is expected

to be approved for the extended adjuvant indication. The potential of immunotherapy in treating tumour disease is great, with attention

being paid to solid tumours. It is malignant melanoma that has played an important role in developing immunotherapy in tumour diseases.

Considerable effort is being made to search for clinically available predictive and prognostic factors capable of selecting patients

suitable for treatment and facilitating its continuous evaluation.

Keywords: immunotherapy, CTLA-4, PD-1, sipuleucel-T, ipilimumab, nivolumab, dendritic cells

Published: March 10, 2015  Show citation